Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Standard Induction Therapy

NCT03315039 is registered in ClinicalTrials.gov with Moleculin Biotech, Inc. as lead sponsor.

NCT NCT03315039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03315039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Standard Induction Therapy
Lead sponsor
Moleculin Biotech, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 28, 2018
Completion date
June 20, 2020
Enrollment
7 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute